However, treatment for prostate cancer cells with SAHA, a potent histone deacetylase (HDAC) inhibitor, results in depletion of EZH2 and induction of RAR beta 2 in prostate cancer cell lines. The gene discussed is HDAC9; the disease is prostate carcinoma.